)
Bharat Biotech announces Covaxin's efficacy rate after final stage trials
Bharat Biotech said that it has concluded the final analysis for its COVID-19 vaccine Covaxin as part of phase-3 clinical trials. The Hyderabad-based pharma company claimed that its indigenous jab demonstrates an overall efficacy of 77.8% against symptomatic infection.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)